Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
Richard Quek1, Suzanne George21Visiting Fellow, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 2Clinical Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USAAbstract: In the last decade a tremendous amount has been learne...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2010
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/36531c7ae35848f485ca0f49aff90e57 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Richard Quek1, Suzanne George21Visiting Fellow, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 2Clinical Director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA, USAAbstract: In the last decade a tremendous amount has been learned about the biology and treatment of gastrointestinal stromal tumor (GIST). Imatinib mesylate has revolutionized the treatment of metastatic GIST. In addition, the role of imatinib in localized GIST has gained much interest and may improve patient outcomes. Additionally, research efforts aimed at understanding the biology and the molecular heterogeneity of GIST both at initial presentation and at the time of resistance to imatinib, has helped guide rational approaches to treatment as well as future efforts aimed at treating imatinib-resistant GIST.Keywords: gastrointestinal stromal tumors, GIST, review, imatinib, tyrosine kinase inhibitor, TKI |
|---|